Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG01 and Gemcitabine in Resected Pancreatic Cancer
NCT02261714Phase 2Completed
- Sponsor
- Targovax
- Start
- Dec 2012
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ras peptide vaccine in pancreatic adenocarcinoma (PDAC), sponsored by Targovax. Primary endpoints: Patients' Safety During Study at 2 years and Patients' Immune Response at 2 years. Started Dec 2012; status: completed.
02
Drugs
ras peptide vaccine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02261714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261714.